Clinical Trial Update: New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia) [Phase 3]

View source ↗

Summary

Phase 3 trial completion update for a new Pfizer antibiotic targeting pneumococcal community-acquired pneumonia due to Streptococcus pneumoniae.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Pneumococcal Pneumonia

Drugs mentioned

• Pfizer antibiotic

Snippet

Sponsor: Pfizer | Conditions: Pneumonia, Pneumococcal, Community Acquired Infections | Phase 3 | Status: COMPLETED